Resource Summary Report

Generated by NIF on Sep 7, 2026

NCI-H1648

RRID:CVCL_1482
Type: Cell Line

Proper Citation

RRID:CVCL_1482

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1482

Proper Citation: RRID:CVCL_1482

Description: Cell line NCI-H1648 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung adenocarcinoma

Defining Citation: PMID:1311061, PMID:8806092, PMID:9559342, PMID:10987304, PMID:11030152, PMID:16187286, PMID:18083107, PMID:19472407, PMID:20164919, PMID:20557307, PMID:22460905, PMID:22961666, PMID:25485619, PMID:25877200, PMID:26589293, PMID:27397505, PMID:28196595, PMID:29681454, PMID:30038707, PMID:30894373, PMID:31068700, PMID:31803961, PMID:35839778

Comments: Population: African American., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H1648

Synonyms: H1648, H-1648, NCIH1648

Cross References: CLO:CLO_0008006, EFO:EFO_0003119, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5882, BioSample:SAMN03473271, BioSample:SAMN10988142, cancercelllines:CVCL_1482, Cell_Model_Passport:SIDM00746, ChEMBL-Cells:CHEMBL3308315, ChEMBL-Targets:CHEMBL2366214, Cosmic:687799, Cosmic:877244, Cosmic:877428,

Cosmic:903597, Cosmic:931372, Cosmic:980979, Cosmic:1028941, Cosmic:1032451, Cosmic:1146882, Cosmic:1152511, Cosmic:1154594, Cosmic:1219083, Cosmic:1239886, Cosmic:1891893, Cosmic:1995529, Cosmic:2125235, Cosmic:2628355, Cosmic:2629444, Cosmic-CLP:687799, DepMap:ACH-000766, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:687799, GEO:GSM62326, GEO:GSM108817, GEO:GSM108818, GEO:GSM253366, GEO:GSM434268, GEO:GSM794323, GEO:GSM817085, GEO:GSM887372, GEO:GSM888450, GEO:GSM1670180, IARC_TP53:499, IARC_TP53:21403, IGRhCellID:H1648GEO, LiGeA:CCLE_277, LINCS_HMS:50032, LINCS_LDP:LCL-1632, PharmacoDB:NCIH1648_1027_2019, PRIDE:PXD030304, Progenetix:CVCL_1482, PubChem_Cell_line:CVCL_1482, Wikidata:Q54907837

ID: CVCL_1482

Record Creation Time: 20220427T220838+0000

Record Last Update: 20260905T181242+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H1648.

No alerts have been found for NCI-H1648.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Jeong J, et al. (2025) NSD2 inhibitors rewire chromatin to treat lung and pancreatic cancers. Nature.

Pulice JL, et al. (2025) Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma. Molecular cell, 85(7), 1311.

Knoll N, et al. (2025) CRISPR-Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer. Cancer research, 85(18), 3518.

Pelos G, et al. (2024) Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment. International journal of cancer, 154(6), 1029.

Aboulkassim T, et al. (2023) A NRF2 inhibitor selectively sensitizes KEAP1 mutant tumor cells to cisplatin and gefitinib by restoring NRF2-inhibitory function of KEAP1 mutants. Cell reports, 42(9), 113104.

Orlando E, et al. (2022) An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapies. Cellular and molecular life sciences : CMLS, 80(1), 6.

Yenerall P, et al. (2020) RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer. Cell chemical biology, 27(1), 105.

Ge P, et al. (2019) miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer. BMC cancer, 19(1), 1203.